These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 11706701)

  • 21. Studies of the antibody on the platelet surface in patients with factor-VIII inhibitors.
    Ali MA; Blajchman MA
    Br J Haematol; 1972 Mar; 22(3):365-8. PubMed ID: 4552218
    [No Abstract]   [Full Text] [Related]  

  • 22. Epitope specificity and inactivation mechanisms of factor VIII inhibitor antibodies.
    Scandella D
    Vox Sang; 1999; 77 Suppl 1():17-20. PubMed ID: 10529680
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tolerance to factor VIII inhibitors in hemophilia A patients: a French twist.
    Pascual V; Capra JD
    J Clin Invest; 1996 Mar; 97(6):1357-8. PubMed ID: 8617864
    [No Abstract]   [Full Text] [Related]  

  • 24. [Hemophilia A with factor VIII inhibitor].
    Shima M
    Rinsho Ketsueki; 2003 Feb; 44(2):90-101. PubMed ID: 12692981
    [No Abstract]   [Full Text] [Related]  

  • 25. Antibodies to factor VIII in hemophilia A patients.
    Brackmann HH; Schwaab R; Effenberger W; Hess L; Hanfland P; Oldenburg J
    Vox Sang; 2000; 78 Suppl 2():187-90. PubMed ID: 10938950
    [TBL] [Abstract][Full Text] [Related]  

  • 26. New characteristics of anti-factor VIII inhibitor antibody epitopes and unusual immune responses to Factor VIII.
    Scandella D
    Semin Thromb Hemost; 2002 Jun; 28(3):291-6. PubMed ID: 12098091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A potential new procedure for removing anti-factor VIII antibodies from hemophilic plasma.
    Regnault V; Rivat C; Vallet JP; Francois-Gerard C; Brochier G; Allain JP
    Thromb Res; 1987 Jan; 45(1):51-7. PubMed ID: 3105113
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibitors, what is the risk of treatment intensity?
    Collins PW
    J Thromb Haemost; 2007 Jul; 5(7):1380-2. PubMed ID: 17445122
    [No Abstract]   [Full Text] [Related]  

  • 29. Physiopathology of catalytic antibodies: the case for factor VIII-hydrolyzing immunoglobulin G.
    Wootla B; Dasgupta S; Mallet V; Kazatchkine MD; Nagaraja V; Friboulet A; Kaveri SV; Lacroix-Desmazes S
    Blood Coagul Fibrinolysis; 2006 Jun; 17(4):229-34. PubMed ID: 16651863
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Anti-factor-VIII inhibitors in haemophilia.
    Lancet; 1989 Aug; 2(8659):363-4. PubMed ID: 2569554
    [No Abstract]   [Full Text] [Related]  

  • 31. Detection of two different anti-factor VIII/von Willebrand factor antibodies of the IgA class in a hemophilic patient with a polyclonal factor VIII inhibitor of the IgG class.
    Carmona E; Aznar JA; Jorquera JI; Villanueva MJ; Sánchez-Cuenca JM
    Thromb Res; 1991 Jul; 63(1):73-84. PubMed ID: 1948824
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Suggestions for the management of factor VIII inhibitors.
    Rubinger M; Rivard GE; Teitel J; Walker H;
    Haemophilia; 2000 Jul; 6 Suppl 1():52-9. PubMed ID: 10982269
    [No Abstract]   [Full Text] [Related]  

  • 33. [Transient inhibitors developed in two cases of hemophilia A].
    Fujiwara F; Kanoh G; Ogawa H; Takaya K; Hibi S; Shima M; Yoshioka A; Imashuku S
    Rinsho Ketsueki; 1997 Dec; 38(12):1263-8. PubMed ID: 9455145
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rapid acquisition of immunologic tolerance to factor VIII and disappearance of anti-factor VIII IgG4 after prophylactic therapy in a hemophilia A patient with high-titer factor VIII inhibitor.
    Moorehead PC; Thibeault L; Tuttle A; Grabell J; Dwyre L; Silva M; James P; Lillicrap D
    J Pediatr Hematol Oncol; 2015 May; 37(4):e220-2. PubMed ID: 25411864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [A rare case of factor VIII-inhibitor formation].
    Eckstein A; Voss B; Taubert W; Scheja J
    Dtsch Zahnarztl Z; 1986 Apr; 41(4):398-9. PubMed ID: 3091357
    [No Abstract]   [Full Text] [Related]  

  • 36. A preliminary study for isolation of catalytic antibodies by histidine ligand affinity chromatography as an alternative to conventional protein A/G methods.
    Nedonchelle E; Pitiot O; Vijayalakshmi MA
    Appl Biochem Biotechnol; 2000; 83(1-3):287-94; discussion 294-5, 297-313. PubMed ID: 10826967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Factor VIII inhibitors.
    Lollar P; Healey JF; Barrow RT; Parker ET
    Adv Exp Med Biol; 2001; 489():65-73. PubMed ID: 11554592
    [No Abstract]   [Full Text] [Related]  

  • 38. Inhibitors to factor VIII in a family with mild hemophilia: molecular characterization and response to factor VIII and desmopressin.
    Santagostino E; Gringeri A; Tagliavacca L; Mannucci PM
    Thromb Haemost; 1995 Aug; 74(2):619-21. PubMed ID: 8584995
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients.
    Hoyer LW; Scandella D
    Semin Hematol; 1994 Apr; 31(2 Suppl 4):1-5. PubMed ID: 7524160
    [No Abstract]   [Full Text] [Related]  

  • 40. Kinetics of the inhibitor of factor VIII:C in patients with hemophilia A. A study of the cooperative group of hemophilia.
    Ambriz-Fernández R; Reyna-Fregoso MP; Pizzuto-Chávez J; Rodríguez-Moyado H; Farfán-Canto JM; Trueba-Christy E; Collazo-Jaloma J
    Arch Invest Med (Mex); 1985; 16(3):225-35. PubMed ID: 3938639
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.